Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that new data on the company’s ...

Fulcrum Therapeutics Inc (FULC) reports reduced expenses and advances in clinical trials, positioning itself for future growth despite competitive challenges.

In children with sickle cell disease ... are ongoing The role of exposure from infancy to chronic infection, hemolysis, poor nutrition and oxyhemoglobin desaturation in determining the risk ...

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today reported business highlights and financial ...

Clinical features of sickle cell disease are chronic hemolytic anemia and vaso-occlusive, which can lead to pain, poor quality of life, organ damage and early mortality. There is an urgent need ...

Fulcrum Therapeutics, Inc. ( NASDAQ: FULC) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Alex Sapir – President and Chief Executive Officer Alan Musso – Chief Financial Officer Iain Fraser – ...

Agios Pharmaceuticals AGIO incurred a loss of $1.55 per share in the first quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $1.80. In the year-ago quarter, the company had ...

Purpose: The recent discovery of the HFE gene and its association with hereditary hemochromatosis has renewed the attention directed to iron-overload diseases. Population screening for hereditary ...

Autosplenectomy happens in sickle cell disease when the misshapen cells block the ... There are a number of different disorders like hereditary spherocytosis or autoimmune hemolytic anemia (AIHA) ...